Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Arrowhead Pharmaceuticals Inc
Depreciation & Amortization
Arrowhead Pharmaceuticals Inc
Depreciation & Amortization Peer Comparison
Competitive Depreciation & Amortization Analysis
Latest Figures & CAGR of Competitors
Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
|
Depreciation & Amortization
-$15.9m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-25%
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Arrowhead Pharmaceuticals Inc's Depreciation & Amortization?
Depreciation & Amortization
-15.9m
USD
Based on the financial report for Mar 31, 2024, Arrowhead Pharmaceuticals Inc's Depreciation & Amortization amounts to -15.9m USD.
What is Arrowhead Pharmaceuticals Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
-25%
Over the last year, the Depreciation & Amortization growth was -49%. The average annual Depreciation & Amortization growth rates for Arrowhead Pharmaceuticals Inc have been -32% over the past three years , and -25% over the past ten years .